Takara Bio Inc. (JP:4974)
:4974
Want to see JP:4974 full AI Analyst Report?
Top Page
Takara Bio Inc.
(4974)
Select Model
Select Model
Rating:52Neutral
Price Target:
¥1,112.00
▲(41.48% Upside)
Action:ReiteratedDate:02/18/26
The score is held back primarily by deteriorating profitability and deeply negative free cash flow, despite a conservatively levered balance sheet. Technicals are strong with price well above moving averages and a positive MACD, but overbought RSI increases near-term downside risk. Valuation support is limited due to losses (negative P/E), with only modest help from the dividend yield.
Positive Factors
Recurring consumables & workflow stickiness
Takara Bio's core sales derive from consumables and reagents that are consumed per experiment and embedded in lab protocols. This creates durable repeat revenue, high switching costs from revalidation, and steady demand as labs maintain validated workflows, supporting long-term revenue visibility.
Negative Factors
Deeply negative free cash flow
Persistent negative free cash flow of ~-¥8.4B signals heavy investment, capex, or working-capital strain. This reduces the firm's ability to self-fund operations and R&D, may force cash reserves draws or external financing, and undermines capital allocation flexibility over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables & workflow stickiness
Takara Bio's core sales derive from consumables and reagents that are consumed per experiment and embedded in lab protocols. This creates durable repeat revenue, high switching costs from revalidation, and steady demand as labs maintain validated workflows, supporting long-term revenue visibility.
Read all positive factors
Takara Bio Inc. (4974) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥137.51B
Dividend Yield2.18%
Average Volume (3M)357.12K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue Growth2.55%
EPS Growth-13747.38%
CountryJP
Employees1,838
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-59.79
Shares Outstanding120,415,600
10 Day Avg. Volume362,320
30 Day Avg. Volume357,120
Financial Highlights & Ratios
PEG Ratio-3.23
Price to Book (P/B)0.86
Price to Sales (P/S)2.21
P/FCF Ratio-24.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9
Revenue Forecast (FY)¥43.61B
Takara Bio Inc. Business Overview & Revenue Model
Company Description
Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops resea...
How the Company Makes Money
Takara Bio generates revenue through multiple key streams, primarily focused on the sale of its life sciences research products and services. The company makes money by offering a wide array of molecular biology reagents and kits, which are essent...
Takara Bio Inc. Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
72
Positive
Cash Flow
33
Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 44.15B | 45.04B | 43.51B | 78.14B | 67.70B | 46.09B |
| Gross Profit | 23.84B | 26.07B | 26.91B | 44.77B | 49.21B | 31.87B |
| EBITDA | -92.00M | 6.50B | 7.90B | 25.98B | 31.70B | 17.36B |
| Net Income | -7.20B | 1.04B | 1.48B | 16.01B | 19.85B | 9.55B |
Balance Sheet | ||||||
| Total Assets | 130.48B | 127.61B | 123.21B | 129.20B | 115.71B | 90.98B |
| Cash, Cash Equivalents and Short-Term Investments | 19.83B | 29.55B | 35.42B | 51.85B | 23.63B | 25.99B |
| Total Debt | 10.00B | 1.10B | 968.00M | 972.00M | 1.05B | 1.14B |
| Total Liabilities | 29.15B | 11.76B | 11.42B | 16.75B | 19.65B | 16.68B |
| Stockholders Equity | 101.05B | 115.50B | 111.50B | 112.22B | 95.87B | 74.18B |
Cash Flow | ||||||
| Free Cash Flow | -8.38B | -4.03B | -11.07B | 31.15B | -5.55B | 5.10B |
| Operating Cash Flow | 4.23B | 5.84B | 1.71B | 36.90B | 6.99B | 13.94B |
| Investing Cash Flow | -19.94B | -10.91B | -13.04B | -6.69B | -7.07B | -3.78B |
| Financing Cash Flow | 6.14B | -2.26B | -5.23B | -4.12B | -2.07B | -1.10B |
Takara Bio Inc. Technical Analysis
Positive
786.00
Price Trends
1093.36
Positive
949.89
Positive
923.65
Positive
Market Momentum
11.36
Positive
65.67
Neutral
36.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4974, the sentiment is Positive. The current price of 786 is below the 20-day moving average (MA) of 1144.45, below the 50-day MA of 1093.36, and below the 200-day MA of 923.65, indicating a neutral trend. The MACD of 11.36 indicates Positive momentum. The RSI at 65.67 is Neutral, neither overbought nor oversold. The STOCH value of 36.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4974.
Takara Bio Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ¥16.55B | 120.78 | ― | ― | -7.33% | -167.46% | |
52 Neutral | ¥137.51B | -8.84 | ― | 2.18% | 2.55% | -13747.38% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥46.44B | 3.63 | ― | ― | -81.43% | 48.15% | |
50 Neutral | ¥23.88B | -33.89 | ― | ― | -11.11% | -187.80% | |
49 Neutral | ¥10.45B | -8.85 | ― | ― | -56.71% | -23.09% | |
45 Neutral | ¥18.80B | -11.30 | ― | ― | ― | 13.18% |
* Healthcare Sector Average
JP:4974
Takara Bio Inc.
1,142.00
315.00
38.09%
JP:4593
Healios KK
344.00
22.00
6.83%
JP:4599
StemRIM Inc.
300.00
-9.00
-2.91%
JP:4978
ReproCELL Inc.
174.00
37.00
27.01%
JP:7774
Japan Tissue Engineering Co., Ltd.
588.00
-39.00
-6.22%
JP:7776
CellSeed Inc.
268.00
-254.00
-48.66%
Takara Bio Inc. Corporate Events
Takara Bio Board Backs Parent’s Tender Offer, Paving Way for Delisting
Feb 13, 2026
Takara Bio Inc.’s board has endorsed a tender offer by its parent company, Takara Holdings Inc., recommending that shareholders tender their shares at ¥1,150 per share. The move is part of a plan for Takara Holdings to acquire all remai...
Takara Bio Deepens Losses, Maintains Full-Year Forecast and Dividend Suspension
Feb 13, 2026
Takara Bio Inc. reported nine-month results to December 31, 2025 showing net sales of ¥28.39 billion, down 3.0% year on year, and a deepening loss, with operating loss widening to ¥4.86 billion and net loss attributable to owners of the ...
Takara Bio Swings to Deep Loss, Confirms Forecast and Scraps Dividend
Feb 13, 2026
Takara Bio reported consolidated net sales of ¥28.39 billion for the nine months ended December 31, 2025, down 3.0% year on year, and posted operating and ordinary losses of ¥4.85 billion and ¥5.09 billion, respectively. Profit attr...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.